불임 진단 시장 - 전략적 인사이트와 예측(2026-2035년)

The Fertility Diagnostics Market is expected to grow at a CAGR of 10.6% from a market value of USD 4.70 billion in 2026 to USD 11.61 billion in 2035.

The fertility diagnostics market is undergoing significant transformation driven by the paradigm shift toward comprehensive reproductive health evaluation, the increasing prevalence of infertility, and the growing adoption of assisted reproductive technologies. The market's evolution is characterized by the recognition that accurate diagnostic assessment of both partners is essential for optimizing fertility treatment planning and improving clinical outcomes. The convergence of advanced immunoassays, molecular diagnostics, genetic testing, and digital health platforms is enabling more precise, accessible, and comprehensive fertility assessment. Healthcare systems are expanding fertility diagnostic capabilities as delayed parenthood and rising infertility awareness increase demand for early evaluation. The market is witnessing significant investment in automated laboratory systems, reproductive genetic testing, and AI-enabled diagnostic tools, positioning fertility diagnostics as a critical component of reproductive healthcare and precision medicine.

Market Drivers

• The increasing infertility burden is expanding diagnostic demand and driving market growth. Infertility affects a substantial proportion of the global reproductive-age population, making early diagnostic evaluation an essential component of reproductive healthcare. Healthcare providers are increasingly recommending comprehensive fertility assessments because delayed diagnosis often reduces treatment success and increases healthcare costs. Clinical laboratories therefore are expanding hormonal, molecular, and genetic testing capabilities to support earlier diagnosis. This trend strengthens demand for standardized diagnostic platforms capable of delivering reproducible and clinically actionable results, resulting in sustained growth in fertility diagnostic utilization. The expansion of assisted reproductive technology is further accelerating market growth through increased diagnostic complexity. Assisted reproductive technology relies on accurate diagnostic information before treatment selection because embryo transfer success depends on understanding multiple reproductive factors. Fertility centers are increasingly incorporating ovarian reserve biomarkers, endocrine profiling, genetic testing, and advanced semen analysis into routine clinical workflows. This expansion increases demand for integrated diagnostic platforms capable of supporting multiple analytical techniques within a single laboratory. Molecular and genetic diagnostics are transforming fertility assessment through improved individualized treatment planning. Traditional fertility testing identifies hormonal abnormalities, whereas molecular diagnostics reveal genetic factors affecting reproductive outcomes. Clinical specialists are increasingly integrating carrier screening, chromosomal analysis, and infertility-associated gene panels because these tests improve individualized treatment planning. Laboratories therefore are investing in NGS workflows and advanced molecular platforms that complement conventional endocrine testing. Digital fertility monitoring is extending diagnostics beyond clinical laboratories through connected health technologies. Connected fertility monitoring technologies allow continuous collection of reproductive health data between clinical visits. Consumers are increasingly adopting home-based hormone monitoring and digital ovulation tracking because these solutions improve convenience while supporting physician-guided care.

Market Restraints

• Limited reimbursement for advanced fertility diagnostics restricts routine adoption. Many healthcare systems prioritize treatment over comprehensive diagnostic workups, increasing out-of-pocket expenses for patients seeking molecular diagnostics, genetic screening, or advanced sperm function testing. Regulatory requirements for in vitro diagnostics increase commercialization timelines. Manufacturers must generate robust analytical and clinical validation data before introducing new fertility diagnostic assays. Variability in infertility care infrastructure limits market penetration. Access to specialized fertility laboratories remains concentrated in urban and high-income regions. Regulatory complexities across different jurisdictions create compliance burdens for manufacturers seeking to commercialize new diagnostic solutions.

Technology and Product Insights

• The technology landscape is characterized by the growing importance of integrated laboratory workflows, molecular diagnostics, and digital health platforms. Immunoassays remain essential for reproductive hormone measurement, including AMH, FSH, LH, estradiol, and progesterone. Molecular diagnostics are expanding for genetic screening and infertility-associated gene analysis. Ultrasound imaging continues supporting structural and functional reproductive assessment. Automated semen analysis is improving male fertility assessment standardization. NGS is expanding for comprehensive reproductive genetic testing. The segment analysis reveals that diagnostic instruments form the technological foundation because laboratories require highly standardized analytical platforms. Fertility centers are increasingly replacing standalone analyzers with automated immunoassay systems, molecular diagnostic platforms, digital semen analyzers, and integrated laboratory automation. Female fertility testing accounts for a substantial portion of diagnostic demand because evaluation of ovulatory function, hormonal status, ovarian reserve, and reproductive anatomy remains essential. Fertility specialists are increasingly incorporating AMH testing, FSH analysis, LH assessment, estradiol measurement, progesterone evaluation, and reproductive imaging into standardized diagnostic pathways. Ovulation assessment remains one of the most frequently performed fertility investigations because accurate identification of ovulatory function guides natural conception planning and assisted reproductive treatment. Fertility clinics represent the leading end-user segment, with hospitals and diagnostic laboratories expanding testing capabilities. The integration of AI is becoming increasingly important because AI-assisted interpretation is being integrated into semen analysis, embryo assessment support, and laboratory workflow optimization to improve consistency and reduce manual variability.

Competitive and Strategic Outlook

• The competitive landscape features established diagnostics and life science companies alongside specialized reproductive health, molecular, and digital fertility providers. Roche maintains a strong strategic position through its integrated diagnostics business, global laboratory presence, and extensive immunodiagnostics portfolio, combining highly automated analytical systems with clinically validated biomarker assays that support reproductive endocrinology and fertility assessment. Thermo Fisher Scientific distinguishes itself through its broad life sciences portfolio, molecular diagnostics expertise, and leadership in genetic analysis technologies that support reproductive medicine, providing advanced sequencing platforms, PCR technologies, capillary electrophoresis systems, and laboratory automation solutions. Abbott maintains a competitive presence through its well-established immunoassay platforms and extensive global diagnostics network, with its Alinity i and ARCHITECT immunoassay systems supporting fertility-related hormone testing. Danaher participates through its operating companies, particularly Beckman Coulter Diagnostics and Cepheid, which provide laboratory automation, immunodiagnostics, and molecular diagnostic technologies. Siemens Healthineers leverages its expertise in laboratory diagnostics, automation, and digital healthcare to support fertility assessment across clinical laboratories worldwide. Merck occupies a distinctive position because it combines fertility therapeutics with digital reproductive health solutions and scientific collaboration across ART. Companies are pursuing product portfolio expansion through innovation in automated immunoassays, reproductive genetic testing, and AI-enabled diagnostic tools. Recent key developments include Inception Fertility announcing MySpermBank to expand access to donor sperm services nationwide. Inito launched the InSight Wireless Reader as a Wi-Fi-enabled at-home fertility hormone reader trained on more than 40 million data points. FIGO introduced the Fertility Passport as a documentation tool to help patients and providers track fertility investigations and treatments across clinics and health systems. Geographic expansion remains a key strategic priority, with companies targeting rapidly growing Asia Pacific and emerging markets where fertility infrastructure is expanding.

Short Conclusion

• The fertility diagnostics market is positioned for sustained growth driven by the convergence of infertility burden, ART expansion, and technological innovation. The transition from single-parameter testing toward integrated diagnostic ecosystems represents a fundamental shift in reproductive healthcare. While challenges related to reimbursement variability, regulatory requirements, and infrastructure limitations persist, strategic investments in technology, automation, and digital integration are creating durable competitive advantages for market leaders. The long-term market outlook remains positive, with fertility diagnostics evolving into a critical component of reproductive healthcare, supporting personalized fertility management, treatment optimization, and improved patient outcomes across global healthcare systems.

Key Benefits of this Report

• Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

• Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation, and trade analysis
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Market Snapshot
• 1.2 Key Findings
• 1.3 Analyst Insights
• 1.4 Strategic Recommendations

2. Research Methodology

• 2.1 Research Design
• 2.2 Data Collection Methodology
• 2.3 Market Size Estimation
• 2.4 Forecasting Model
• 2.5 Assumptions & Limitations

3. Global Fertility Diagnostics Market Overview, Size & Forecast

• 3.1 Market Definition & Scope
• 3.2 Fertility Diagnostics Industry Overview
• 3.3 Industry Evolution
• 3.4 Key Market Trends
• 3.5 Historical Market Size Analysis (2021-2025)
• 3.6 Market Forecast Analysis (2026-2035)
• 3.7 Infertility Burden and Unmet Diagnostic Needs
• 3.8 Epidemiology and Prevalence Analysis
  • 3.8.1 Infertility Prevalence
  • 3.8.2 Diagnosed Patient Population
• 3.9 Diagnostic Testing Volume Analysis
• 3.10 Patient Journey Analysis
• 3.11 Fertility Diagnostic Pathway and Clinical Practice

4. Market Dynamics

• 4.1 Market Drivers
• 4.2 Market Restraints
• 4.3 Market Opportunities
• 4.4 Market Challenges

5. Industry Landscape

• 5.1 Industry Value Chain Analysis
• 5.2 Pricing Analysis
• 5.3 Reimbursement Landscape

6. Innovation Landscape

• 6.1 Emerging Diagnostic Technologies
• 6.2 Product Innovation
• 6.3 Clinical Trial Analysis
• 6.4 Pipeline Analysis
• 6.5 Artificial Intelligence Integration in Fertility Diagnostics
• 6.6 Digital Health Integration in Fertility Assessment

7. Regulatory Landscape

• 7.1 Regulatory Framework
• 7.2 Approval Pathways
• 7.3 Compliance Requirements

8. Global Fertility Diagnostics Market Landscape Analysis

• 8.1 Analysis by Technology Platform
• 8.2 Analysis by Biomarker
• 8.3 Analysis by Sample Type
• 8.4 Analysis by Clinical Application
• 8.5 Analysis by Testing Methodology

9. Global Fertility Diagnostics Market Segment Analysis (2021-2035)

• 9.1 By Product Type
  • 9.1.1 Instruments
  • 9.1.2 Consumables & Reagents
  • 9.1.3 Rapid Test Kits / Home Testing Kits
  • 9.1.4 Software & Services
• 9.2 By Test Type
  • 9.2.1 Female Fertility Testing
  • 9.2.2 Male Fertility Testing
  • 9.2.3 Couple Fertility Testing
• 9.3 By Technology
  • 9.3.1 Immunoassays
  • 9.3.2 Molecular Diagnostics
  • 9.3.3 Ultrasound Imaging
  • 9.3.4 Automated Semen Analysis
  • 9.3.5 Next-Generation Sequencing (NGS)
  • 9.3.6 Other Technologies
• 9.4 By Diagnostic Application
  • 9.4.1 Ovulation Assessment
  • 9.4.2 Ovarian Reserve Assessment
  • 9.4.3 Hormonal Evaluation
  • 9.4.4 Male Fertility Assessment
  • 9.4.5 Genetic Screening for Infertility
  • 9.4.6 Preconception Fertility Assessment
• 9.5 By End User
  • 9.5.1 Fertility Clinics
  • 9.5.2 Hospitals
  • 9.5.3 Diagnostic Laboratories
  • 9.5.4 Home Care Settings
  • 9.5.5 Others

10. Global Fertility Diagnostics Market Geographical Analysis (2021-2035)

• 10.1 North America
• 10.2 Europe
• 10.3 Asia-Pacific
• 10.4 South America
• 10.5 Middle East & Africa

11. Global Fertility Diagnostics Market Country Analysis (2021-2035)

• 11.1 United States
• 11.2 Canada
• 11.3 Germany
• 11.4 United Kingdom
• 11.5 France
• 11.6 Italy
• 11.7 Spain
• 11.8 Japan
• 11.9 China
• 11.10 India
• 11.11 South Korea
• 11.12 Australia
• 11.13 Brazil
• 11.14 Mexico
• 11.15 Saudi Arabia

12. Competitive Landscape

• 12.1 Market Share Analysis
• 12.2 Strategic Developments
• 12.3 Mergers & Acquisitions, Partnerships & Collaborations
• 12.4 Product Launches

13. Company Profiles

• 13.1 F. Hoffmann-La Roche Ltd.
• 13.2 Thermo Fisher Scientific Inc.
• 13.3 Abbott Laboratories
• 13.4 Danaher Corporation
• 13.5 Siemens Healthineers AG
• 13.6 bioMerieux SA
• 13.7 Vitrolife AB
• 13.8 FUJIFILM Irvine Scientific
• 13.9 Ferring Holding SA
• 13.10 Merck KGaA

14. Global Fertility Diagnostics Market Commercial Forecast Analysis

• 14.1 Ovulation Prediction Kits
• 14.2 Fertility Monitors
• 14.3 Semen Analysis Systems
• 14.4 Ovarian Reserve Testing
• 14.5 Hormone Testing
• 14.6 Genetic Fertility Testing
• 14.7 Fertility Imaging Systems

15. Investment & Funding Analysis

• 15.1 Venture Capital Trends
• 15.2 Government Funding
• 15.3 R&D Investments

16. Future Outlook

• 16.1 Key Growth Opportunities
• 16.2 Future Industry Trends